U.S. Markets open in 4 hrs 7 mins

SUPN’s Product Portfolio and Financial Guidance

Daniel Collins
SUPN’s Product Portfolio and Financial Guidance

Supernus Pharmaceuticals’ (SUPN) Trokendi XR generated revenues of $76.4 million in the second quarter, compared to $56.0 million in the second quarter of 2017, reflecting ~36.4% YoY (year-over-year) growth.